Incyte Stock Analysis

INCY -  USA Stock  

USD 75.11  1.80  2.34%

The modest gains experienced by current holders of Incyte Corp may raise some interest from investors. The stock closed today at a share price of 75.11 on 1,022,108 in trading volume. The company management teams have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in April. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.78. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Please see Risk vs Return Analysis.
The Incyte Corp stock analysis report makes it easy to digest most publicly released information about Incyte Corp and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Incyte Stock analysis module also helps to analyze the Incyte Corp price relationship with some important fundamental indicators such as market cap and management efficiency.

Incyte Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.52. Incyte Corp had not issued any dividends in recent years. The entity had 2:1 split on the 1st of September 2000. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. To learn more about Incyte Corp call Herve Hoppenot at 302 498 6700 or check out

Incyte Corp Quarterly Cost of Revenue

42.61 Million


Incyte Corp Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Incyte Corp's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Incyte Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Over 95.0% of the company shares are owned by institutional investors
Latest headline from FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients - MarketWatch

Incyte Corp Upcoming and Recent Events

Earnings reports are used by Incyte Corp to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Incyte Corp previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Incyte Largest EPS Surprises

Earnings surprises can significantly impact Incyte Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Incyte Corp SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Incyte Corp prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Incyte Corp investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Incyte Corp specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
21st of April 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of March 2022
Unclassified Corporate Event
14th of February 2022
Unclassified Corporate Event. Unclassified Corporate Event
11th of February 2022
Unclassified Corporate Event
10th of February 2022
Unclassified Corporate Event
8th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
4th of February 2022
Unclassified Corporate Event

Incyte Corp Thematic Classifications

In addition to having Incyte Corp stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Incyte Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 16.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte Corp's market, we take the total number of its shares issued and multiply it by Incyte Corp's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Incyte Profitablity

Incyte Corp's profitability indicators refer to fundamental financial ratios that showcase Incyte Corp's ability to generate income relative to its revenue or operating costs. If, let's say, Incyte Corp is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Incyte Corp's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Incyte Corp's profitability requires more research than a typical breakdown of Incyte Corp's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 31.76 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 22.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.22.
Last ReportedProjected for 2022
Return on Investment 19.31  20.84 
Return on Average Assets 0.23  0.25 
Return on Average Equity 0.30  0.29 
Return on Invested Capital 0.44  0.48 
Return on Sales 0.19  0.21 

Management Efficiency

The entity has return on total asset (ROA) of 8.82 % which means that it generated profit of $8.82 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 29.73 %, meaning that it created $29.73 on every $100 dollars invested by stockholders. Incyte Corp management efficiency ratios could be used to measure how well incyte corp manages its routine affairs as well as how well it operates its assets and liabilities. Incyte Corp Return on Investment is fairly stable at the moment as compared to the past year. Incyte Corp reported Return on Investment of 19.31 in 2021. Return on Average Assets is likely to rise to 0.25 in 2022, whereas Return on Average Equity is likely to drop 0.29 in 2022. Incyte Corp Average Assets are fairly stable at the moment as compared to the past year. Incyte Corp reported Average Assets of 4.17 Billion in 2021. Tangible Asset Value is likely to rise to about 5 B in 2022, whereas Revenue to Assets are likely to drop 0.58 in 2022.
Last ReportedProjected for 2022
Book Value per Share 17.10  18.45 
Enterprise Value over EBIT 25.00  26.97 
Enterprise Value over EBITDA 22.61  24.39 
Price to Book Value 4.30  4.64 
Tangible Assets Book Value per Share 20.99  22.65 
Enterprise Value14.2 B15.1 B
Tangible Asset Value4.6 BB

Technical Drivers

As of the 24th of May, Incyte Corp retains the Downside Deviation of 1.81, risk adjusted performance of 0.1628, and Market Risk Adjusted Performance of 0.2846. Incyte Corp technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Incyte Corp, which can be compared to its competitors. Please check out Incyte Corp market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Incyte Corp is priced fairly, providing market reflects its last-minute price of 75.11 per share. Given that Incyte Corp has jensen alpha of 0.2752, we strongly advise you to confirm Incyte Corp's regular market performance to make sure the company can sustain itself at a future point.

Incyte Corp Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Incyte Corp highest and lowest values attained during the given period.

Incyte Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Incyte Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Baker Bros Advisors Lp over two weeks ago via Macroaxis 
Purchase by Baker Bros Advisors Lp of 6100 shares of Incyte Corp
Maria Pasquale over a month ago via Macroaxis 
Payment of 517 shares by Maria Pasquale of Incyte Corp subject to Rule 16b-3
Paul Clancy over a month ago via Macroaxis 
Acquisition by Paul Clancy of 326 shares of Incyte Corp subject to Rule 16b-3
Tray Thomas over two months ago via Macroaxis 
Incyte Corp exotic insider transaction detected
Baker Bros Advisors Lp over two months ago via Macroaxis 
Exercise or conversion by Baker Bros Advisors Lp of 20000 shares of Incyte Corp subject to Rule 16b-3
Baker Bros Advisors Lp over three months ago via Macroaxis 
Purchase by Baker Bros Advisors Lp of 92234 shares of Incyte Corp
Maria Pasquale over three months ago via Macroaxis 
Acquisition by Maria Pasquale of 14463 shares of Incyte Corp subject to Rule 16b-3
Christiana Stamoulis over three months ago via Macroaxis 
Payment of 331 shares by Christiana Stamoulis of Incyte Corp subject to Rule 16b-3
Baker Bros Advisors Lp over three months ago via Macroaxis 
Purchase by Baker Bros Advisors Lp of 182326 shares of Incyte Corp
Dickinson Jonathan Elliott over three months ago via Macroaxis 
Sale by Dickinson Jonathan Elliott of 7375 shares of Incyte Corp
Morrissey Michael James over three months ago via Macroaxis 
Payment of tradable shares by Morrissey Michael James of Incyte Corp subject to Rule 16b-3
Morrissey Michael James over three months ago via Macroaxis 
Acquisition by Morrissey Michael James of 6959 shares of Incyte Corp subject to Rule 16b-3

Incyte Corp Predictive Daily Indicators

Incyte Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Incyte Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Incyte Corp Forecast Models

Incyte Corp time-series forecasting models is one of many Incyte Corp's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Incyte Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Incyte Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Incyte Corp stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Incyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Incyte Corp. By using and applying Incyte Stock analysis, traders can create a robust methodology for identifying Incyte entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 20.86  22.50 
EBITDA Margin 0.21  0.23 
Gross Margin 0.95  0.91 
Profit Margin 0.32  0.34 
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people.

Current Incyte Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Incyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Incyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Incyte Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Incyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Incyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Incyte Corp, talking to its executives and customers, or listening to Incyte conference calls.
Incyte Analyst Advice Details

Incyte Stock Analysis Indicators

Incyte Corp stock analysis indicators help investors evaluate how Incyte Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Incyte Corp shares will generate the highest return on investment. By understating and applying Incyte Corp stock analysis, traders can identify Incyte Corp position entry and exit signals to maximize returns.
Quick Ratio3.47
Fifty Two Week Low61.91
Revenue Growth9.30%
Average Daily Volume Last 10 Day1.41M
Shares Short Prior Month4.6M
Average Daily Volume In Three Month1.45M
Earnings Growth275.50%
Shares Percent Shares Out2.65%
Earnings Quarterly Growth276.30%
Gross Margins44.87%
Forward Price Earnings16.14
Short Percent Of Float3.21%
Float Shares366.99M
Fifty Two Week High88.26
Fifty Day Average77.23
Enterprise Value To Ebitda46.83
Two Hundred Day Average72.08
Enterprise Value To Revenue10.35
Please see Risk vs Return Analysis. Note that the Incyte Corp information on this page should be used as a complementary analysis to other Incyte Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Incyte Stock analysis

When running Incyte Corp price analysis, check to measure Incyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte Corp is operating at the current time. Most of Incyte Corp's value examination focuses on studying past and present price action to predict the probability of Incyte Corp's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Incyte Corp's price. Additionally, you may evaluate how the addition of Incyte Corp to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Incyte Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte Corp. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Incyte Corp is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte Corp's value that differs from its market value or its book value, called intrinsic value, which is Incyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte Corp's market value can be influenced by many factors that don't directly affect Incyte Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine Incyte Corp value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.